DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for pharmaceutical and medical device clients for use as raw materials in their products under the LACTEL brand.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone408-777-1417
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$18.56 million
Profitability
Miscellaneous
Employees88
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
DURECT (NASDAQ:DRRX) Frequently Asked Questions
What is DURECT's stock symbol?
DURECT trades on the NASDAQ under the ticker symbol "DRRX."
How were DURECT's earnings last quarter?
DURECT Co. (NASDAQ:DRRX) posted its earnings results on Thursday, August, 1st. The specialty pharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.05) by $0.01. The specialty pharmaceutical company earned $3.99 million during the quarter, compared to analyst estimates of $4.05 million. DURECT had a negative net margin of 123.22% and a negative return on equity of 116.97%. View DURECT's Earnings History.
When is DURECT's next earnings date?
What price target have analysts set for DRRX?
3 brokers have issued 12 month price targets for DURECT's stock. Their forecasts range from $2.10 to $5.00. On average, they anticipate DURECT's share price to reach $3.53 in the next twelve months. This suggests a possible upside of 91.0% from the stock's current price. View Analyst Price Targets for DURECT.
What is the consensus analysts' recommendation for DURECT?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DURECT in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for DURECT.
Has DURECT been receiving favorable news coverage?
Media coverage about DRRX stock has trended very negative on Wednesday, InfoTrie reports. The research group rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. DURECT earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave news articles about the specialty pharmaceutical company a news buzz of 8.0 out of 10, meaning that recent news coverage is very likely to have an impact on the company's share price in the next few days. View News Stories for DURECT.
Are investors shorting DURECT?
DURECT saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 1,370,000 shares, an increase of 79.3% from the August 30th total of 763,900 shares. Based on an average daily volume of 1,160,000 shares, the days-to-cover ratio is presently 1.2 days. Currently, 1.0% of the shares of the stock are short sold. View DURECT's Current Options Chain.
Who are some of DURECT's key competitors?
Some companies that are related to DURECT include Opko Health (OPK), BELLUS Health (BLUSF), Enanta Pharmaceuticals (ENTA), Radius Health (RDUS), Turning Point Therapeutics (TPTX), Zymeworks (ZYME), Innoviva (INVA), Esperion Therapeutics (ESPR), ArQule (ARQL), Dicerna Pharmaceuticals (DRNA), Theravance Biopharma (TBPH), Gossamer Bio (GOSS), AnaptysBio (ANAB), TherapeuticsMD (TXMD) and Amphastar Pharmaceuticals (AMPH).
What other stocks do shareholders of DURECT own?
Who are DURECT's key executives?
DURECT's management team includes the folowing people:
- Dr. James E. Brown, Co-Founder, CEO, Pres & Director (Age 62)
- Mr. Matthew J. Hogan, CFO & Sec. (Age 59)
- Ms. Judy R. Joice, Sr. VP of Operations & Corp. Quality Assurance (Age 62)
- Mr. Michael H. Arenberg, Chief Financial Officer (Age 49)
- Dr. John W. Gibson B.S., M.S., VP of Birmingham Operations & Principal Scientist
How do I buy shares of DURECT?
Shares of DRRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is DURECT's stock price today?
One share of DRRX stock can currently be purchased for approximately $1.85.
How big of a company is DURECT?
DURECT has a market capitalization of $355.09 million and generates $18.56 million in revenue each year. The specialty pharmaceutical company earns $-25,320,000.00 in net income (profit) each year or ($0.16) on an earnings per share basis. DURECT employs 88 workers across the globe.View Additional Information About DURECT.
What is DURECT's official website?
How can I contact DURECT?
DURECT's mailing address is 10260 BUBB RD, CUPERTINO CA, 95014. The specialty pharmaceutical company can be reached via phone at 408-777-1417.
MarketBeat Community Rating for DURECT (NASDAQ DRRX)
MarketBeat's community ratings are surveys of what our community members think about DURECT and other stocks. Vote "Outperform" if you believe DRRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DRRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
